All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Recovery comparison

Apelin vs BPC-157

An educational, source-based comparison of Apelin and BPC-157 — how each peptide works, what it's researched for, and what to know before going deeper.

Cardiovascular · Metabolic
Apelin

Endogenous peptide researched for heart and metabolic function.

Mechanism

An endogenous peptide ligand for the APJ receptor, widely expressed in cardiovascular and metabolic tissues. Research indicates roles in cardiac contractility, angiogenesis, blood pressure regulation, and insulin sensitivity.

Research areas
  • Heart failure and cardiac contractility
  • Pulmonary arterial hypertension
  • Insulin sensitivity and glucose uptake
  • Angiogenesis and vascular repair
Considerations
  • Primarily preclinical and early clinical research.
  • Not FDA-approved for any indication.
Full Apelin profile →
Tissue Repair · Gastrointestinal
BPC-157

Body Protection Compound studied for gut and tissue support.

Mechanism

A pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. Research suggests it modulates the nitric oxide system, upregulates growth hormone receptors in injured tissue, and promotes angiogenesis (formation of new blood vessels) — mechanisms associated with accelerated tendon, ligament, muscle, and intestinal mucosa repair in preclinical models.

Research areas
  • Tendon-to-bone healing
  • Ligament and muscle recovery
  • Gastric ulcer protection
  • Inflammatory bowel models
  • Neuroprotection (rodent)
Considerations
  • Human clinical trials are limited — most research is preclinical.
  • Not FDA-approved for human therapeutic use.
  • Quality, purity, and dosing of compounded peptides vary widely.
Full BPC-157 profile →

Trial-evidence rating

Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.

Apelin
Limited

Two cited studies; independent replication needed.

2 cited studies
BPC-157
Moderate

3 cited studies; evidence base is growing.

3 cited studies

Study-by-study comparison

PeptideStudySourceYearSummary
ApelinApelin in heart failure: a new therapeutic targetJournal of the American College of Cardiology2019Reviewed cardioprotective mechanisms and therapeutic potential in heart failure.
ApelinApelin improves insulin sensitivity in obese modelsDiabetes2014Enhanced glucose uptake and insulin signaling in adipose and muscle tissue.
BPC-157Pentadecapeptide BPC 157 and the central nervous systemNeural Regeneration Research2022Review of neuroprotective and neurorepair signaling pathways observed in animal models.
BPC-157Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia/reperfusion in ratsJournal of Physiology - Paris2018Demonstrated mucosal protective effects and accelerated recovery from induced colitis.
BPC-157BPC 157 and tendon-to-bone healingJournal of Orthopaedic Research2010Improved biomechanical recovery of transected Achilles tendons in rats.

Side-effect & safety grid

Apelin
  • Primarily preclinical and early clinical research.
  • Not FDA-approved for any indication.
BPC-157
  • Human clinical trials are limited — most research is preclinical.
  • Not FDA-approved for human therapeutic use.
  • Quality, purity, and dosing of compounded peptides vary widely.

Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.

Apelin vs BPC-157 — Key differences

  • Class: Apelin is classified as Cardiovascular · Metabolic, while BPC-157 is Tissue Repair · Gastrointestinal.
  • Primary research focus: Apelinheart failure and cardiac contractility; BPC-157tendon-to-bone healing.
  • Tag: Cardiovascular · Metabolic vs Recovery.

BPC-157 Research Protocol Table

Structured summary of dosing, routes, and durations as described in published research and FDA labels. Educational reference only — not dosing guidance.

ContextPopulationRouteDoseDurationNotes
Tendon and ligament recovery (preclinical)Rodent models (rat, mouse)Subcutaneous or intraperitoneal10 mcg/kg/day10–14 days in most cited studiesAnimal data only; cited human-grade safety or efficacy evidence is not established.
GI mucosal recovery (preclinical)Rodent modelsOral or intragastric in some studies; subcutaneous in others10–50 mcg/kg/day depending on study5–14 daysFrequently cited in gut-recovery literature; remains preclinical.
Anecdotal human research-use (non-clinical literature)Adults, mixed; off-labelSubcutaneousCommonly cited 250–500 mcg, 1–2× daily2–6 week cycles in user reportsNot validated by controlled human trials; FDA has flagged BPC-157 outside approved drug pathways.

BPC-157 Research — Female vs Male Studies

How published BPC-157 research breaks down by sex, including which populations were studied and what trial data exist.

Female research

Female-specific clinical trial data for BPC-157 are essentially absent. Preclinical rodent studies have included female animals but do not isolate sex-based outcomes.

Studied populations
  • Female rodents in tissue-recovery models
  • No published human RCTs stratified by sex.
  • Pregnancy, lactation, and hormonal-cycle effects have not been characterized.

Male research

Male-specific clinical data are similarly limited. Most cited animal studies use male rodents for tendon, ligament, and GI models.

Studied populations
  • Male rodents in tendon/ligament/GI repair models
  • No published human RCTs in men.
  • Anecdotal human use reports skew male but do not constitute clinical evidence.

BPC-157 — Frequently Asked Questions

Is BPC-157 FDA-approved?+

No. BPC-157 is not FDA-approved for any indication. It has appeared on the FDA's bulk-substance review lists as not eligible for traditional compounding under current evidence.

What does research suggest BPC-157 is studied for?+

Most cited BPC-157 research involves rodent models of tendon, ligament, and gastrointestinal mucosal recovery. Human controlled trial data remain very limited.

Are BPC-157 protocols the same for men and women?+

Published literature does not separate BPC-157 dosing by sex. There are no controlled human trials establishing sex-specific protocols.

Related comparisons